摘要
嵌合抗原受体(chimeric antigen receptor,CAR)-自然杀伤(natural killer,NK)细胞疗法作为新兴的免疫治疗手段,在肿瘤治疗领域展现出巨大潜力,尤其在腹部恶性肿瘤领域实现了从基础研究到临床应用的重要突破。本文概述CAR-NK细胞疗法的基本情况,系统梳理其在肝癌、胃癌、结直肠癌及胰腺癌等腹部肿瘤中的相关研究进展,并探讨HER2、MSLN、CEA和EGFR等关键受体在开发新型CAR-NK疗法中的潜力,旨在为腹部肿瘤患者探索新的治疗路径,改善其临床预后,推动分子肿瘤学领域向精准诊疗方向持续发展。
As an emerging immunotherapy modality,chimeric antigen receptor(CAR)⁃natural killer(NK)cell therapy demonstrates significant potential in tumor treatment,achieving a pivotal breakthrough from foundational research to clinical application,particu⁃larly in the treatment of abdominal malignancies.This article provides an overview of CAR⁃NK cell therapy and systematically summa⁃rizes the research progress in its application to abdominal tumors,including hepatocellular carcinoma(HCC),gastric cancer,colorectal can⁃cer,and pancreatic cancer.It also explores the potential of key receptors including HER2,MSLN,CEA,and EGFR in developing novel CAR⁃NK therapies.This aims to explore new treatment pathways for patients with abdominal tumors,improve their clinical prognosis,and promote the field of molecular oncology towards precision diagnosis and treatment.
作者
牛旭东
王丙萍
韩晶晶
冀亚东
周杰
明星
高艳伟
NIU Xudong;WANG Bingping;HAN Jingjing;JI Yadong;ZHOU Jie;MING Xing;GAO Yanwei(Graduate School of Baotou Medical College,Inner Mongolia University of Science and Technology,Baotou 014040,China;Department of Abdominal Oncology Surgery,Inner Mongolia People′s Hospital,Hohhot 010017,China;Graduate School of Inner Mongolia Medical University,Hohhot 010107,China)
出处
《中国癌症防治杂志》
2025年第6期747-754,共8页
CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
基金
公立医院科研联合基金科技项目(2023GLLH0106)
内蒙古自治区科技计划项目(2022YFSH0055)
内蒙古自治区人民医院博士科研启动资金项目(2024BS04)
内蒙古自治区卫生健康科技计划项目(2025WSJK007)。
关键词
肝细胞癌
胃癌
结直肠癌
胰腺癌
CAR-NK细胞疗法
腹部肿瘤
精准医学
Hepatocellular carcinoma
Gastric cancer
Colorectal cancer
Pancreatic cancer
CAR⁃NK cell therapy
Abdominal tumors
Precision medicine
